Emergent BioSolutions (EBS)

Emergent BioSolutions (EBS) is a specialty pharmaceutical company that develops, manufactures, and commercializes a variety of specialized products for use in biodefense and commercial markets in the US and internationally. EBS’s Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent for the treatment of suspected or documented exposure to botulinum neurotoxin; Anthrax Immune Globulin (AIG) Intravenous to treat toxemia associated with inhalational anthrax; Vaccinia Immune Globulin Intravenous for addressing adverse events from smallpox vaccination; and RSDL (reactive skin decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. The Biosciences segment markets WinRho to treat autoimmune platelet disorder and hemolytic diseases in newborns; HepaGam B for the prevention of Hepatitis B reinfection after liver transplantation, and for use as a post-exposure prophylaxis; Varizig for post-exposure prophylaxis of chickenpox; Episil to treat pain associated with oral mucositis; and Ixinity, a therapeutic to prevent bleeding episodes in people with hemophilia

Published Reports

EBS 4Q18 rev
EBS FY19 guidance rev
EBS 3Q18 rev
EBS Adapt Pharma acquisition rev
EBS acquisition of PaxVax rev
EBS-2Q18-rev.pdf
EBS 1Q18 rev
EBS 4Q17 rev
EBS Investor Analyst day rev
EBS FDA approval edit
EBS-Raxibacumab-Acquistion-rev.pdf
EBS ACAM2000 Acquisition
EBS 1Q17 rev
EBS follow-on contract 12.8.16 rev
ebs-3q16-rev
EBS USG solicitation 6 22 16 rev
EBS 1Q16 rev
EBS 4Q15 rev
EBS 3Q15 rev
EBS 2Q15 rev
EBS Lansing visit 10 6 15 rev
EBS management day 7.13-14.15 rev
EBS initiation 051115 rev2